1846G&gt;A polymorphism of<i>CYP2D6</i>gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study

Сычев, Д. А.; Burashnikova, I. S.; Казаков, Р. Е.

doi:10.1515/dmpt-2016-0027

Cited by 9 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We excluded 20 studies that showed positive associations with AP-induced movement disorders without differentiating with which ones [ 13 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ].…”

Section: Methodsmentioning

confidence: 99%

Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review

Насырова

Vaiman

Repkina

et al. 2023

Genes

View full text Add to dashboard Cite

Antipsychotic-induced akathisia (AIA) is a movement disorder characterized by a subjective feeling of inner restlessness or nervousness with an irresistible urge to move, resulting in repetitive movements of the limbs and torso, while taking antipsychotics (APs). In recent years, there have been some associative genetic studies of the predisposition to the development of AIA. Objective: The goal of our study was to review the results of associative genetic and genome-wide studies and to systematize and update the knowledge on the genetic predictors of AIA in patients with schizophrenia (Sch). Methods: We searched full-text publications in PubMed, Web of Science, Springer, Google Scholar, and e-Library databases from 1977 to 2022. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) quality scale was used for the critical selection of the studies. Results: We identified 37 articles, of which 3 were included in the review. Thus, the C allele of rs1800498 (59414 C>T) and the A allele of rs1800497 (17316 G>A) (TaqIA) from the DRD2 gene as well as the TT genotype rs13212041 (77461407 C>T) from the HTR1B gene were found to be associated with AIA. Conclusions: Uncovering the genetic biomarkers of AIA may provide a key to developing a strategy for the personalized prevention and treatment of this adverse neurological drug reaction of APs in patients with Sch in real clinical practice.

show abstract

Section: Methodsmentioning

confidence: 99%

Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review

Насырова

Vaiman

Repkina

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

“…9 Although a great number of CYP2D6 polymorphisms have been described to the moment, the frequency of many of them is relatively low (≤ 1%). 10 The most common variant of the CYP2D6 gene causing an absence of the enzymatic activity is the 1846A ( CYP2D6*4 ) allele ( rs3892097 ). 11 It was formed because of single nucleotide replacement 1846G>A in the genomic DNA sequence (NCBI Reference Sequence: NG_008376.3).…”

Section: Introductionmentioning

confidence: 99%

Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder

Застрожин

Skryabin²,

Смирнов

et al. 2021

American Journal of Therapeutics

View full text Add to dashboard Cite

Background: Previous studies have shown that cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of fluvoxamine, the activity of which is highly dependent, inter alia, on the polymorphism of the gene encoding it. The objective of our study was to investigate the effect of 1846G.A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder.Study question: Efficacy and safety of fluvoxamine depend on the polymorphism of CYP2D6 gene in patients with major depressive disorder.Study design: Our study enrolled 96 male patients with depressive disorders comorbid with alcohol use disorder. Patients were examined on days 1, 9, and 16 of fluvoxamine therapy.Measures and Outcomes: Treatment efficacy was evaluated using the validated psychometric scales. Therapy safety was assessed using the UKU Side-Effect Rating Scale. For genotyping and estimation of the microRNA (miRNA) plasma levels, we performed the real-time polymerase chain reaction. The activity of CYP2D6 was evaluated using the HPLC-MS/MS method by the content of the endogenous substrate of given isoenzyme and its metabolite in urine (6-hydroxy-1,2,3,4tetrahydro-b-carboline/pinoline ratio).Results: Our study revealed the statistically significant results for the treatment efficacy evaluation [the Hamilton Depression Rating Scale scores at the end of the treatment course: (GG) 2.0 (1.0-4.0) and (GA) 5.0 (4.0-7.0), P , 0.001]. Analysis of the results of the pharmacotranscriptomic part of the study did not show the statistically significant difference in the hsa-miR-370-3p plasma levels in patients with different genotypes: (GG) 26.9 (15.0-32.2), (GA) 31.8 (22.7-33.7), P 5 0.247. In addition, we evaluated the relationship between the CYP2D6 enzymatic activity (as evaluated by 6-hydroxy-1,2,3,4-tetrahydro-b-carboline/ pinoline ratio measurement) and the hsa-miR-370-3p plasma concentration: rs 5 20.243, P 5 0.017.

show abstract

Clinically relevant pharmacogenetic markers in Tatars and Balkars

Мирзаев

Burashnikova²,

Shikaleva³

et al. 2020

Mol Biol Rep

View full text Add to dashboard Cite

1846G>A polymorphism ofCYP2D6gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study

Abstract: Further well-designed pharmacogenetic studies in different Russian regions are needed to improve psychotropic therapy safety and to establish evidence-based indications for pharmacogenetic testing in clinical practice.

Cited by 9 publications

References 28 publications

Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review

Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review

Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder

Clinically relevant pharmacogenetic markers in Tatars and Balkars

Contact Info

Product

Resources

About